Cloud-Based Infrastructure to Drive the Development of Personalized Drugs for Hearing Loss

Cloud-Based Infrastructure to Drive the Development of Personalized Drugs for Hearing Loss

Cloud-Based Infrastructure to Drive the Development of Personalized Drugs for Hearing Loss
We hope that you enjoyed hearing from industry leaders about how they are working to expedite therapy development, incorporate digital therapeutics at scale, and improve patient outcomes. For more information on other ways AWS can help your healthcare and life sciences organization, visit us at: https://amzn.to/2G4vZes or contact the team at: [email protected]

Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development, and translational research platform for hearing and balance disorders. Decibel’s lead therapeutic candidates, DB020 and DB-041, are designed to prevent hearing loss resulting from cisplatin and aminoglycoside antibiotics, respectively. Decibel is also advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all.

View on YouTube

Sharing is caring!

Comments are closed.